Hyloris’ Dispute With AltaThera Reaches Another Milestone After Arbitration

The Panel’s Final Verdict Clears Hyloris Of Financial Liabilities

 
• By Adam Zamecnik

Hyloris’ dispute with AltaThera over the cardiovascular drug Sotalol IV has reached another milestone with a final verdict from an arbitration panel, which cleared Hyloris of financial liabilities while also denying its own claims.

Illustrative image of arbitration
• Source: Shutterstock

The dispute between Hyloris Pharmaceuticals and AltaThera Pharmaceuticals over claims linked to the cardiovascular drug Sotalol IV has seen another key development after the issuing of a final opinion from an arbitration panel between the two players.

Hyloris originally partnered with AltaThera for the US commercialization of its compound Sotalol IV, which is an intravenous formulation of the otherwise oral dug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin